Diane Stroehmann is Vice President of Regulatory Affairs and Global Patient Safety at Ironwood. Prior to joining the company in August 2019, Ms. Stroehmann was Chief of Staff to the CEO and Head of Regulatory Affairs and Quality at Sienna Pharmaceuticals from 2016 to 2019. Prior to Sienna, Ms. Stroehmann was Vice President of Regulatory Affairs, Pharmacovigilance and Research Compliance at Kythera Biopharmaceuticals from September 2013 to October 2015 when it was acquired by Allergan. At Kythera, Ms. Stroehmann led the successful submission and approval of Kybella® in the U.S. and Canada in addition to the submission of multiple international marketing applications. She also had oversight for FDA Advisory Committee preparations for Kybella which led to a unanimous vote in favor of approval. Ms. Stroehmann was Head of Regulatory Affairs at Medicis Pharmaceutical Corporation where she worked for nearly ten years. Over the course of her career, Ms. Stroehmann has amassed experience in all phases of pharmaceutical development – from discovery through clinical development to marketing approval. She played a critical role in multiple NDAs, BLAs, and PMAs at Medicis that eventually led to successful product approvals in dermatology and aesthetic medicine, including Solodyn®, Vanos®, Dysport®, and Restylane®. She has worked on drug products in a variety of therapeutic areas including the development of pharmaceutical therapies via the company’s orphan drug subsidiary, Ucyclyd Pharma. Ms. Stroehmann earned a B.S. in biology at the University of Illinois Urbana-Champaign and an M.S. in regulatory affairs from San Diego State University.